SLNO Soleno Therapeutics | $69.05
+2.5% | 3/27/2025 | Target Raised by | Laidlaw | Analyst Yale Jen | Buy -> Buy | $75.00 -> $105.00 | High | View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 3/27/2025 |
NVCT Nuvectis Pharma | $9.73
+0.8% | 3/17/2025 | Initiated by | Laidlaw | Analyst Yale Jen | Buy | $19.00 | High | View details for Laidlaw rating of Nuvectis Pharma (NASDAQ:NVCT) on 3/17/2025 |
LFWD ReWalk Robotics | $1.84
-2.1% | 2/10/2025 | Initiated by | Laidlaw | Analyst Yale Jen | Buy | $10.00 | High | View details for Laidlaw rating of ReWalk Robotics (NASDAQ:LFWD) on 2/10/2025 |
ABVX ABIVAX Société Anonyme | $6.66
-6.1% | 7/29/2024 | Initiated by | Laidlaw | - | Buy | $48.00 | Low | View details for Laidlaw rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 7/29/2024 |
MEIP MEI Pharma | $2.30
-0.9% | 7/23/2024 | Downgraded by | Laidlaw | - | Buy -> Hold | | Low | View details for Laidlaw rating of MEI Pharma (NASDAQ:MEIP) on 7/23/2024 |
AFMD Affimed | $0.80
-3.1% | 6/13/2024 | Target Raised by | Laidlaw | - | Buy | $15.00 -> $25.00 | Low | View details for Laidlaw rating of Affimed (NASDAQ:AFMD) on 6/13/2024 |
PHGE BiomX | $0.54
-27.5% | 5/28/2024 | Initiated by | Laidlaw | - | Buy | $25.00 | N/A | View details for Laidlaw rating of BiomX (NYSEMKT:PHGE) on 5/28/2024 |
INAB IN8bio | $0.21
-1.5% | 3/18/2024 | Initiated by | Laidlaw | - | Buy | $7.50 | Low | View details for Laidlaw rating of IN8bio (NASDAQ:INAB) on 3/18/2024 |
CING Cingulate | $4.17
-4.1% | 12/22/2023 | Downgraded by | Laidlaw | - | Buy -> Hold | | Low | View details for Laidlaw rating of Cingulate (NASDAQ:CING) on 12/22/2023 |
CING Cingulate | $4.17
-4.1% | 1/20/2022 | Initiated by | Laidlaw | - | Buy | $170.00 | High | View details for Laidlaw rating of Cingulate (NASDAQ:CING) on 1/20/2022 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
AFMD Affimed | $0.80
-3.1% | 8/9/2020 | Reiterated by | Laidlaw | - | Market Perform -> Buy | $100.00 | Medium | View details for Laidlaw rating of Affimed (NASDAQ:AFMD) on 8/9/2020 |
CRIS Curis | $2.62
+8.5% | 7/29/2020 | Initiated by | Laidlaw | - | Buy | $100.00 | Medium | View details for Laidlaw rating of Curis (NASDAQ:CRIS) on 7/29/2020 |
SLNO Soleno Therapeutics | $69.05
+2.5% | 6/5/2020 | Reiterated by | Laidlaw | Analyst Yale Jen | Buy | $150.00 | Low | View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 6/5/2020 |
DCTH Delcath Systems | $13.26
-1.0% | 6/1/2020 | Initiated by | Laidlaw | - | Buy | $19.00 | High | View details for Laidlaw rating of Delcath Systems (NASDAQ:DCTH) on 6/1/2020 |
ALDX Aldeyra Therapeutics | $6.21
-0.7% | 5/26/2020 | Reiterated by | Laidlaw | - | Buy | $30.00 | Low | View details for Laidlaw rating of Aldeyra Therapeutics (NASDAQ:ALDX) on 5/26/2020 |
SLNO Soleno Therapeutics | $69.05
+2.5% | 12/23/2019 | Initiated by | Laidlaw | Analyst Francois Brisebois | Buy | | High | View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 12/23/2019 |
EYPT EyePoint Pharmaceuticals | $6.04
-0.3% | 11/4/2019 | Initiated by | Laidlaw | - | Buy | $500.00 | High | View details for Laidlaw rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 11/4/2019 |
AVDL Avadel Pharmaceuticals | $8.25
+0.9% | 9/24/2019 | Target Raised by | Laidlaw | Analyst Francois Brisebois | Buy | $3.00 -> $6.00 | Low | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 9/24/2019 |
TLSA Tiziana Life Sciences | $1.17
+2.5% | 9/10/2019 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $20.00 | N/A | View details for Laidlaw rating of Tiziana Life Sciences (NASDAQ:TLSA) on 9/10/2019 |
EBS Emergent BioSolutions | $4.75
-3.6% | 9/4/2019 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $72.00 | Low | View details for Laidlaw rating of Emergent BioSolutions (NYSE:EBS) on 9/4/2019 |
CLSD Clearside Biomedical | $0.99
-3.7% | 8/13/2019 | Downgraded by | Laidlaw | - | Buy -> Hold | | Low | View details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 8/13/2019 |
AVDL Avadel Pharmaceuticals | $8.25
+0.9% | 8/12/2019 | Upgraded by | Laidlaw | Analyst Francois Brisebois | Hold -> Buy | $3.00 | Low | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 8/12/2019 |
SLNO Soleno Therapeutics | $69.05
+2.5% | 7/8/2019 | Initiated by | Laidlaw | - | Buy | $150.00 | High | View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 7/8/2019 |
AFMD Affimed | $0.80
-3.1% | 7/3/2019 | Target Set by | Laidlaw | Analyst Yale Jen | Buy | $100.00 | Low | View details for Laidlaw rating of Affimed (NASDAQ:AFMD) on 7/3/2019 |
CARA Cara Therapeutics | $5.34
-0.8% | 5/29/2019 | Target Raised by | Laidlaw | Analyst James Molloy | Buy | $312.00 -> $384.00 | Low | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 5/29/2019 |
AVDL Avadel Pharmaceuticals | $8.25
+0.9% | 3/18/2019 | Target Set by | Laidlaw | Analyst Francois Brisebois | Hold | $2.00 | Medium | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 3/18/2019 |
BSGM BioSig Technologies | $0.62
+5.1% | 2/20/2019 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $110.00 | Medium | View details for Laidlaw rating of BioSig Technologies (NASDAQ:BSGM) on 2/20/2019 |
ARCT Arcturus Therapeutics | $11.95
-0.4% | 2/19/2019 | Initiated by | Laidlaw | - | Buy | | Low | View details for Laidlaw rating of Arcturus Therapeutics (NASDAQ:ARCT) on 2/19/2019 |
CARA Cara Therapeutics | $5.34
-0.8% | 12/20/2018 | Target Set by | Laidlaw | Analyst James Molloy | Buy | $360.00 | Low | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 12/20/2018 |
TLSA Tiziana Life Sciences | $1.17
+2.5% | 12/17/2018 | Initiated by | Laidlaw | - | Buy -> Buy | | High | View details for Laidlaw rating of Tiziana Life Sciences (NASDAQ:TLSA) on 12/17/2018 |
CLSD Clearside Biomedical | $0.99
-3.7% | 11/6/2018 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $5.00 | Low | View details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 11/6/2018 |
AVDL Avadel Pharmaceuticals | $8.25
+0.9% | 11/6/2018 | Downgraded by | Laidlaw | - | Buy -> Hold | $6.00 | High | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 11/6/2018 |
CLSD Clearside Biomedical | $0.99
-3.7% | 7/16/2018 | Initiated by | Laidlaw | - | Buy | $18.00 | High | View details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 7/16/2018 |
VKTX Viking Therapeutics | $26.10
-0.1% | 6/1/2018 | Target Raised by | Laidlaw | - | Buy | $10.00 -> $15.00 | High | View details for Laidlaw rating of Viking Therapeutics (NASDAQ:VKTX) on 6/1/2018 |
CARA Cara Therapeutics | $5.34
-0.8% | 5/24/2018 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $312.00 | Low | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 5/24/2018 |
MEIP MEI Pharma | $2.30
-0.9% | 4/12/2018 | Initiated by | Laidlaw | - | Buy | $140.00 | High | View details for Laidlaw rating of MEI Pharma (NASDAQ:MEIP) on 4/12/2018 |
MRNS Marinus Pharmaceuticals | $0.55
-0.2% | 12/14/2017 | Initiated by | Laidlaw | - | Buy -> Buy | $72.00 | High | View details for Laidlaw rating of Marinus Pharmaceuticals (NASDAQ:MRNS) on 12/14/2017 |
FRX Fennec Pharmaceuticals | C$9.05
-4.3% | 11/29/2017 | Initiated by | Laidlaw | - | Buy | C$22.00 | N/A | View details for Laidlaw rating of Fennec Pharmaceuticals (TSE:FRX) on 11/29/2017 |
FENC Fennec Pharmaceuticals | $6.46
-0.2% | 11/29/2017 | Initiated by | Laidlaw | - | Buy -> Buy | $22.00 | High | View details for Laidlaw rating of Fennec Pharmaceuticals (NASDAQ:FENC) on 11/29/2017 |
EYPT EyePoint Pharmaceuticals | $6.04
-0.3% | 11/8/2017 | Initiated by | Laidlaw | - | Buy | $500.00 | N/A | View details for Laidlaw rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 11/8/2017 |
The Trump Dump is starting; Get out of stocks now? (Ad) The first 365 days of the Trump presidency…
Will be the best time to get rich in American history. If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a |
DRRX DURECT | $0.81
| 10/20/2017 | Target Lowered by | Laidlaw | - | Buy -> Buy | $30.00 -> $20.00 | N/A | View details for Laidlaw rating of DURECT (NASDAQ:DRRX) on 10/20/2017 |
IONS Ionis Pharmaceuticals | $31.33
-0.5% | 8/14/2017 | Reiterated by | Laidlaw | - | Buy | $65.00 | Low | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 8/14/2017 |
ICAD iCAD | $2.13
-0.5% | 7/25/2017 | Reiterated by | Laidlaw | - | Buy | $11.00 | Medium | View details for Laidlaw rating of iCAD (NASDAQ:ICAD) on 7/25/2017 |
CARA Cara Therapeutics | $5.34
-0.8% | 6/30/2017 | Target Lowered by | Laidlaw | - | Buy | $420.00 -> $360.00 | High | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 6/30/2017 |
CARA Cara Therapeutics | $5.34
-0.8% | 3/28/2017 | Reiterated by | Laidlaw | - | Buy -> Buy | $240.00 -> $420.00 | High | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 3/28/2017 |
CARA Cara Therapeutics | $5.34
-0.8% | 3/10/2017 | Target Raised by | Laidlaw | - | Buy -> Buy | $204.00 -> $240.00 | Medium | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 3/10/2017 |
OPK OPKO Health | $1.74
-0.3% | 1/3/2017 | Reiterated by | Laidlaw | - | Buy | $22.00 -> $19.00 | N/A | View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 1/3/2017 |
IONS Ionis Pharmaceuticals | $31.33
-0.5% | 12/27/2016 | Target Raised by | Laidlaw | - | Buy | $59.00 -> $65.00 | N/A | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 12/27/2016 |
AXON Axon Enterprise | $542.11
-1.6% | 12/20/2016 | Initiated by | Laidlaw | - | Sell | $7.50 | N/A | View details for Laidlaw rating of Axon Enterprise (NASDAQ:AXON) on 12/20/2016 |
VKTX Viking Therapeutics | $26.10
-0.1% | 8/11/2016 | Target Lowered by | Laidlaw | - | Buy | $20.00 -> $10.00 | N/A | View details for Laidlaw rating of Viking Therapeutics (NASDAQ:VKTX) on 8/11/2016 |
CARA Cara Therapeutics | $5.34
-0.8% | 2/29/2016 | Target Lowered by | Laidlaw | - | Buy | $360.00 -> $204.00 | N/A | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 2/29/2016 |
AVDL Avadel Pharmaceuticals | $8.25
+0.9% | 1/21/2016 | Target Lowered by | Laidlaw | - | Buy | $30.00 -> $25.00 | N/A | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 1/21/2016 |
AFMD Affimed | $0.80
-3.1% | 12/10/2015 | Initiated by | Laidlaw | - | Buy | $150.00 | N/A | View details for Laidlaw rating of Affimed (NASDAQ:AFMD) on 12/10/2015 |
OPK OPKO Health | $1.74
-0.3% | 8/13/2015 | Initiated by | Laidlaw | - | Buy | $22.00 | N/A | View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 8/13/2015 |
OPK OPKO Health | $1.74
-0.3% | 8/12/2015 | Initiated by | Laidlaw | - | Buy | $22.00 | N/A | View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 8/12/2015 |
ALDX Aldeyra Therapeutics | $6.21
-0.7% | 1/26/2015 | Initiated by | Laidlaw | Analyst Yale Jen | Buy | $30.00 | N/A | View details for Laidlaw rating of Aldeyra Therapeutics (NASDAQ:ALDX) on 1/26/2015 |
IONS Ionis Pharmaceuticals | $31.33
-0.5% | 12/9/2014 | Target Raised by | Laidlaw | - | | $65.00 | N/A | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 12/9/2014 |
IONS Ionis Pharmaceuticals | $31.33
-0.5% | 11/25/2014 | Reiterated by | Laidlaw | - | Buy | | N/A | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 11/25/2014 |
IONS Ionis Pharmaceuticals | $31.33
-0.5% | 8/12/2014 | Initiated by | Laidlaw | - | Buy | $52.00 | N/A | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 8/12/2014 |
IOVA Iovance Biotherapeutics | $3.62
-0.4% | 6/30/2014 | Initiated by | Laidlaw | - | Buy | | N/A | View details for Laidlaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 6/30/2014 |
SSYS Stratasys | $10.17
-1.1% | 3/7/2014 | Initiated by | Laidlaw | - | Buy | $145.00 | N/A | View details for Laidlaw rating of Stratasys (NASDAQ:SSYS) on 3/7/2014 |
OMCL Omnicell | $34.97
+1.5% | 3/5/2014 | Target Raised by | Laidlaw | - | Buy | $29.00 -> $34.00 | N/A | View details for Laidlaw rating of Omnicell (NASDAQ:OMCL) on 3/5/2014 |
SRDX Surmodics | $30.47
0.0% | 2/25/2014 | Initiated by | Laidlaw | - | Buy | $30.00 | N/A | View details for Laidlaw rating of Surmodics (NASDAQ:SRDX) on 2/25/2014 |
OMCL Omnicell | $34.97
+1.5% | 1/28/2014 | Target Raised by | Laidlaw | - | Buy | $27.00 -> $29.00 | N/A | View details for Laidlaw rating of Omnicell (NASDAQ:OMCL) on 1/28/2014 |
